Cardiac sarcoidosis and ACM genetic variants coexist with distinct features, highlighting the need for refined clinical ...

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Co. Ltd. patents describe molecular glue degraders reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

Sarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Bitcoin Depot (NASDAQ: BTM) ("Bitcoin Depot” or the "Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today announced it has purchased an additional $5 million in Bitcoin as ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish Sati from the ...

Efzofitimod, the company's first-in-class biologic immunomodulator, is in clinical development for the treatment of interstitial lung diseases or ILD such as pulmonary sarcoidosis. The posters ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...